Isarna Therapeutics enters into a strategic manufacturing agreement with Sanofi
“At Isarna, we are convinced that the best possible manufacturing is critical as we seek to maintain an accelerated timeline for product development,” explained Dr. Philippe Calais, CEO of Isarna Therapeutics. “Having Sanofi as our partner for the production of these exciting new immunotherapy compounds is a firm step forward in the development of the company and is consistent with our strategy to establish key relationships with leaders in the industry.
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.